Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 2/20 | 0.44 |
| ▸ | MAOB | P27338 | 2/20 | 0.44 |
| ▸ | PRKCI | P41743 | 1/20 | 0.44 |
| ▸ | HSD17B1 | P14061 | 3/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 2/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | EP300 | Q09472 | 1/20 | 0.35 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.33 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31125679 | 0.89 | KDM4E (0.41) | MAOAMAOBPRKCIHSD17B1ACHE | |
| SCHEMBL3989388 | 0.89 | KDM4E (0.41) | MAOAMAOBPRKCIHSD17B1ACHE | |
| SCHEMBL9521410 | 0.81 | ACHE (0.53) | MAOAMAOBPRKCIHSD17B1CYP2A6 | |
| SCHEMBL8615195 | 0.81 | MAOA (0.39) | MAOAMAOBPRKCIHSD17B1CYP2A6 | |
| SCHEMBL23783031 | 0.78 | MAOA (0.44) | MAOAMAOBPRKCIHSD17B1CYP2A6 | |
| SCHEMBL13726726 | 0.78 | MAOA (0.37) | MAOAMAOBPRKCIHSD17B1CYP2A6 | |
| SCHEMBL31620328 | 0.78 | MAOA (0.41) | MAOAMAOBPRKCIHSD17B1CYP2A6 | |
| SCHEMBL24687751 | 0.78 | MAOA (0.44) | MAOAMAOBPRKCIHSD17B1CYP2A6 | |
| SCHEMBL31156850 | 0.78 | MAOA (0.49) | MAOAMAOBPRKCIHSD17B1CYP2A6 | |
| SCHEMBL30070449 | 0.78 | MAOA (0.37) | MAOAMAOBPRKCIHSD17B1CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7485655-B2 | 2-Aminothiazole allosteric enhancers of A1 adenosine receptors | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2009-02-03 | — | — | US | disclosed |
| EP-1583530-A4 | 2-AMINOTHIAZOLE ALLOSTERIC ENHANCERS OF A1-ADENOSINE RECEPTORS | UNIV VIRGINIA (US) | 2008-07-23 | — | — | EP | disclosed |
| EP-1583530-A1 | 2-AMINOTHIAZOLE ALLOSTERIC ENHANCERS OF A1-ADENOSINE RECEPTORS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2005-10-12 | — | — | EP | disclosed |
| US-6943183-B2 | 5-substituted tetralones as inhibitors of ras farnesyl transferase | PFIZER INC (US) | 2005-09-13 | — | — | US | disclosed |
| US-20050027125-A1 | 2-Aminothiazole allosteric enhancers of a ?1? adenosine receptors | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-02-03 | — | — | US | disclosed |
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | PHARMACIA CORPORATION | 2004-07-01 | — | — | US | disclosed |
| US-20040044057-A1 | 5- substituted tetralones as inhibitors of ras farnesyl trransferase | WARNER-LAMBERT COMPANY | 2004-03-04 | — | — | US | disclosed |
| WO-2003061655-A1 | 2-AMINOTHIAZOLE ALLOSTERIC ENHANCERS OF A1 ADENOSINE RECEPTORS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2003-07-31 | — | — | WO | disclosed |
| EP-1276725-A2 | 5-SUBSTITUTED TETRALONES AS INHIBITORS OF RAS FARNESYL TRANSFERASE | WARNER-LAMBERT COMPANY (US) | 2003-01-22 | — | — | EP | disclosed |
| WO-2001079180-A2 | 5-SUBSTITUTED TETRALONES AS INHIBITORS OF RAS FARNESYL TRANSFERASE | WARNER-LAMBERT COMPANY (US) | 2001-10-25 | — | — | WO | disclosed |
| EP-0764159-B1 | C -4 AMIDE SUBSTITUTED COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | SMITHKLINE BEECHAM PLC (GB) | 2000-08-09 | — | — | EP | disclosed |
| US-5843989-A | C4 -amide substituted compounds and their use as therapeutic agents | SMITHKLINE BEECHAM P.L.C. (GB) | 1998-12-01 | — | — | US | disclosed |
| EP-0764159-A1 | C -4 AMIDE SUBSTITUTED COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | SMITHKLINE BEECHAM PLC (GB) | 1997-03-26 | — | — | EP | disclosed |
| WO-1995034547-A1 | C-4 AMIDE SUBSTITUTED COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | SMITHKLINE BEECHAM PLC (GB) | 1995-12-21 | — | — | WO | disclosed |
| US-4709095-A | ANTIINFLAMMATORY AGENTS, ANALGESICS, DIURETICS AND HYPOTENSIVE AGENTS | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1987-11-24 | — | — | US | disclosed |
| US-4618683-A | Tetrahydro-6,7-dimethoxy-1H-benz[e]isoinodolines useful in the treatment of hypertension and as sedatives | ABBOTT LABORATORIES (US) | 1986-10-21 | — | — | US | disclosed |
| EP-0191108-A1 | O-AMINOMETHYLPHENOL COMPOUNDS | Yoshitomi Pharmaceutical Industries, Ltd. (JP) | 1986-08-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044057-A1 | 5- substituted tetralones as inhibitors of ras farnesyl trransferase | PTAR1, FNTA, GGPS1 | MAOA 3197/4885MAOB 2947/4885PRKCI 1911/4885 |
| US-20050027125-A1 | 2-Aminothiazole allosteric enhancers of a ?1? adenosine receptors | ADORA1, ADORA2A, ADORA2B | MAOA 1699/4885MAOB 2252/4885PRKCI 2838/4885 |
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | MKNK2, MAPKAPK2, MAP3K2 | MAOA 2249/4885MAOB 1745/4885PRKCI 201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.